Global Blood Therapeutics
NEWS
Global Blood Therapeutics was acquired by Pfizer in August 2022.
Global Blood Therapeutics, Inc. announced that it will present at the following investor conferences in December 2019.
First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy
Ted W. Love, president and chief executive officer of GBT, called the approval of Oxbryta a major milestone for the company and for patients with sickle cell disease.
Global Blood Therapeutics, Inc., announced that on October 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the company’s common stock with a per share exercise price of $46.99 and restricted stock units for an aggregate of 57,050 shares of the company’s common stock.
Global Blood Therapeutics, Inc. announced that four abstracts related to its sickle cell disease research have been accepted for oral and poster presentations during the 47th Annual National Sickle Cell Disease Association of America Convention in Baltimore, taking place October 9-12, 2019.
Global Blood Therapeutics, Inc., announced that it will host an Analyst & Investor Day to provide an update to the investment community on the company’s development and commercial strategy for voxelotor for sickle cell disease.
Global Blood Therapeutics, Inc. announced that it will present at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019, at 10:05 a.m. Eastern Time.
Global Blood Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) seeking accelerated approval for voxelotor, an oral, once-daily therapy in development for the treatment of sickle cell disease (SCD).
Global Blood Therapeutics, Inc. announced that on September 1, 2019, the compensation committee of GBT’s board of directors granted Eric Fink and 8 new employees options to purchase an aggregate of 47,600 shares of the company’s common stock with a per share exercise price of $45.98 and restricted stock units for an aggregate of 54,425 shares of the company’s common stock.
JOBS
IN THE PRESS